Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice.
Vaccines have been recently developed to treat various diseases such as cancer, rheumatoid arthritis and Alzheimer's disease in addition to infectious diseases. However, before use in the clinical setting, vaccines targeting self-antigens must be demonstrated to be effective and safe, evoking a...
Saved in:
Main Authors: | Futoshi Nakagami, Hiroshi Koriyama, Hironori Nakagami, Mariana Kiomy Osako, Munehisa Shimamura, Mariko Kyutoku, Takashi Miyake, Tomohiro Katsuya, Hiromi Rakugi, Ryuichi Morishita |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2013
|
Subjects: | |
Online Access: | https://doaj.org/article/cdcd8e024d3e4ac6869e79224ddf17f6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice
by: Shota Yoshida, et al.
Published: (2020) -
Development of anti-thrombotic vaccine against human S100A9 in rhesus monkey
by: Munehisa Shimamura, et al.
Published: (2021) -
RAGE ligands stimulate angiotensin II type I receptor (AT1) via RAGE/AT1 complex on the cell membrane
by: Serina Yokoyama, et al.
Published: (2021) -
Hepatocyte Growth Factor Prevented High-Fat Diet-Induced Obesity and Improved Insulin Resistance in Mice
by: Jun Muratsu, et al.
Published: (2017) -
Essential role for miR-196a in brown adipogenesis of white fat progenitor cells.
by: Masaki Mori, et al.
Published: (2012)